IonsGate Preclinical Services and InSilicoTrials together to innovate drug discovery
IonsGate and InSilicoTrials together to innovate drug discovery
The partnership will allow Canada’s CRO to leverage cutting-edge technology provided
by the European HealthTech company, in order to innovate and optimize
Canada/Europe, 11 February 2022 – Canadian CRO IonsGate, that is a market leader in preclinical research services, and European life sciences company InSilicoTrials just announced a partnership to leverage innovative technology like Modeling and Simulation.
IonsGate and InSilicoTrials are going to work together in order to optimize preclinical studies relying on innovation and digitalization, as recommended by regulatory bodies – such as FDA and EMA.
InSilicoTrials will provide a complex technology known as Modeling and Simulation to digitalize IonsGate’s drug discovery processes. This will significantly cut the cost and timeframe of preclinical tests while increasing the safety of new molecules.
IonsGate has been conducting ion channels/cell-based assays and tissue-based assays for many years now. Its mission is to characterize proprietary compounds with an integrative approach to cardiac safety and function. IonsGate’s team of experts in drug safety and discovery is constantly helping pharmaceutical companies with experimental design, interpretation of data, and guidance for next step in the drug discovery process.
InSilicoTrials is the first cloud-based platform that provides healthcare companies with easy-to-use tools to perform computational Modeling and Simulation in drug discovery and development. Simulation is a key factor to cut in vitro and in vivo test costs and shorten the go-to-market of new medicines. This enables pharmaceutical companies and CROs to free resources, do more reseach and in the long run find a higher number of new molecules to treat more diseases.
This partnership will allow to combine IonsGate’s in vitro services with InSilicoTrials’ in silico solutions in a cost-effective and highly reliable way, with the objective of accelerating innovation in drug discovery, for the benefit of thousands of patients worldwide.
“We are very excited at the opportunity of bringing in silico methods to the clients of one of Canada’s most prestigious and respected CROs”, says Luca Emili, CEO and Founder of InSilicoTrials. “Our partner has a reputation for offering the most reliable preclinical research services for drug discovery and safety. We believe adding our in silico solutions to their in vitro assays will accelerate the development of new drugs, improve their safety and innovate the whole R&D process”.
InSilicoTrials is a Life science tech company founded in 2018 by a team of life sciences, cybersecurity, and digital innovation experts, which aims to revolutionize the Healthcare sector thanks to an innovative digital simulation platform. Today, the very long and expensive development, as well as the subsequent registration/certification
processes for new drugs and medical devices, are becoming unsustainable, especially for SMEs. Modeling and simulation can reduce these costs up to 50% and greatly accelerate the go-to-market of new products, allowing
companies to exploit patents for a longer period. Regulatory agencies are recommending companies to adopt these practices, but many of these lack the high expertise, expensive software, and IT infrastructure, needed to develop and use models. InSilicoTrials solves these problems by selecting and collecting the best models from top researchers around the world and then by integrating them with the solvers in a scalable IT platform, which makes it easier to use validated models without specific computational knowledge, paying only for the used resources. InSilicoTrials is currently working on five projects funded by the European Union: In Silico World, SimCardioTest, Brainteaser, TranSys and Disc4All.